{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"The Drugs.com Monthly Update Podcast","title":"Drugs.com - Monthly Update August 2026","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/cdcea303\"></iframe>","width":"100%","height":180,"duration":369,"description":"In our August 2026 episode of Drugs.com Monthly Update, we review the latest round of FDA approvals bringing new therapeutic strategies to patients and prescribers.\nmFLUSIVA (influenza vaccine, mRNA): A new mRNA-based seasonal flu vaccine approved for the prevention of influenza disease in adults 50 years of age and older.\nOrzeyful (oveporexton): An innovative orexin receptor 2 agonist approved for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adult patients.\nGenglycos (pariglasgene brecaparvovec-opnr): A novel gene therapy for adults and pediatric patients 8 years and older with glycogen storage disease type Ia to reduce daily cornstarch intake.\nRasonque (daraxonrasib): A broad RAS-targeted medicine approved for previously treated adults with metastatic pancreatic adenocarcinoma.\nBixlenvo (bictegravir and lenacapavir): A once-daily combination antiretroviral tablet for virologically suppressed adults with HIV-1 replacing their current regimen.\nChapters:\nFollow Drugs.com:\nX, Facebook, YouTube\nSign up to our newsletters\nDownload the app","thumbnail_url":"https://img.transistorcdn.com/DIoKA3oI7NY0UzZ45F0V0NkzM-ycfQHBYCciiz9juOc/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mMDAz/YzA5MzEzMjc1MDA5/YjRmMjFmMDA1MjYy/YmZmZC5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}